Wang Cong, Yuan Changji, He Hua, Bai Ou
Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, 130021, China.
Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, 130021, China. Email:
Zhonghua Zhong Liu Za Zhi. 2014 Nov;36(11):858-62.
To evaluate the epidermiology, clinicopathological features and prognosis of primary extra-nodal non-Hodgkin's lymphoma (PE-NHL).
The clinicopathological data of 151 patients diagnosed as PE-NHL in the First Affiliated Hospital of Jilin University between January 2007 and December 2011 were reviewed and analyzed.
The proportion of PE-NHL patients was 58.8% among all the non-Hodgkin's lymphoma cases, with the average age of 52 years, and the male/female ratio was 1.16:1. The most frequently involved site was the stomach (30.5%) followed by nose and sinuses (19.9%) and Waldeyer's ring (17.2%). The most common subtype was diffuse large B-cell lymphoma (DLBCL) (55.0%), followed by NK/T (18.5%) and extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) ( 13.2%). The distribution of clinical stages was as follows: stage I 20.5%, II 29.8%, III 29.1%, and IV 20.5%. Most nasal PE-NHL is in early stages, with a proportion of 76.7% in stages I & II. The 3-year overall survival rate was 73.2% and 3-year progression free survival rate was 46.6% in the PE-DLBCL patients. The International Prognosis Index (IPI) could be used to estimate the prognosis of PE-DLBCL well. Multivariate analysis showed that ESR and curative effect of the first treatment were independent prognostic factors for PE-DLBCL patients.
The incidence of PE-NHL is quite high, and the most common primary extra-nodal site is the gastro-intestinal tract and the most common subtype is diffuse large B-cell lymphoma. Risk groups based on IPI can indicate the prognosis of PE-DLBCL to some extent, but only the ESR and curative effect of the first treatment are confirmed to be independent risk factors.
评估原发性结外非霍奇金淋巴瘤（PE-NHL）的流行病学、临床病理特征及预后。
回顾性分析2007年1月至2011年12月期间在吉林大学第一附属医院确诊为PE-NHL的151例患者的临床病理资料。
PE-NHL患者占所有非霍奇金淋巴瘤病例的58.8%，平均年龄52岁，男女比例为1.16:1。最常累及的部位是胃（30.5%），其次是鼻和鼻窦（19.9%）以及韦氏环（17.2%）。最常见的亚型是弥漫性大B细胞淋巴瘤（DLBCL）（55.0%），其次是NK/T细胞淋巴瘤（18.5%）和黏膜相关淋巴组织结外边缘区B细胞淋巴瘤（MALT）（13.2%）。临床分期分布如下：Ⅰ期20.5%，Ⅱ期29.8%，Ⅲ期29.1%，Ⅳ期20.5%。大多数鼻型PE-NHL处于早期，Ⅰ期和Ⅱ期的比例为76.7%。PE-DLBCL患者的3年总生存率为73.2%，3年无进展生存率为46.6%。国际预后指数（IPI）可较好地评估PE-DLBCL的预后。多因素分析显示，血沉（ESR）和首次治疗疗效是PE-DLBCL患者的独立预后因素。
PE-NHL发病率较高，最常见的原发性结外部位是胃肠道，最常见的亚型是弥漫性大B细胞淋巴瘤。基于IPI的风险分组在一定程度上可提示PE-DLBCL的预后，但仅血沉和首次治疗疗效被确认为独立危险因素。
